Literature DB >> 2096997

Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group.

M A Blankenstein1.   

Abstract

Nine laboratories cooperating in the Receptor Study Group of the EORTC compared results of ligand binding assay supplemented with Scatchard plot analysis (LBA) and enzyme immunoassay (EIA) for the assessment of oestrogen receptors in 1665 breast cancer cytosols. An excellent agreement was observed between results of Scatchard plot analysis and EIA in each laboratory. Linear correlation coefficients of log-transformed data (log [(ER + 10)/10]) ranged from 0.839 to 0.977 (n = 52-373; P less than 0.001); Spearman's R ranged from 0.797 to 0.972 (P less than 0.001). Orthogonal regression analysis on log-transformed data revealed slopes of 0.794 to 1.141 and intercepts of -0.057 to 0.154 corresponding to -1.2 to 4.3 fmole/mg protein. Both assays compared equally well for pre- as well as postmenopausal patients, which confirms that occupied receptors are not extracted during the preparation of cytosol. The percentage discordance in the classification of tumours as ER positive or negative varied from 4.1 to 13.3 when a cut-off value of 10 fmol/mg protein was used, and from 1.4 to 7.5 at a cut-off level of 20. Considerable variations were observed in the actual receptor levels reported by each laboratory. Since these differences occurred in the results of both methods, they are attributed to differences in tissue handling. It is concluded that the ER-EIA is an excellent alternative to Scatchard plot analysis for the assay of oestrogen receptors. It is recommended, however, that laboratories performing assays on samples obtained from patients who are eligible for entrance in EORTC clinical trials and who wish to use the EIA should validate this assay against the Scatchard plot assay in their own setting.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096997     DOI: 10.1007/bf01806289

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study.

Authors:  G Leclercq; H Bojar; J Goussard; R I Nicholson; M F Pichon; A Piffanelli; A Pousette; S Thorpe; M Lonsdorfer
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

2.  Estrogen and progesterone receptor assays in human breast cancer: sources of variation between laboratories.

Authors:  B W Borjesson; R McGinley; T M Foo; C Smyth; M Toppila; P Compton; G A Sarfaty
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

3.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Authors:  J A Foekens; H Portengen; W L van Putten; H A Peters; H L Krijnen; J Alexieva-Figusch; J G Klijn
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

6.  Quantitative immunological detection of estrogen receptors in nuclear pellets from human breast cancer biopsies.

Authors:  S M Thorpe; A E Lykkesfeldt; A Vinterby; M Lonsdorfer
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

7.  Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States.

Authors:  V C Jordan; H I Jacobson; E J Keenan
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  Standardization of steroid receptor assays in human breast cancer--II. Samples with low receptor content.

Authors:  A Koenders; S M Thorpe
Journal:  Eur J Cancer Clin Oncol       Date:  1983-10

9.  Standardization of steroid receptor assays in human breast cancer--III. Selection of reference material for intra- and inter-laboratory quality control.

Authors:  S M Thorpe; A Koenders
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08

10.  A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays.

Authors:  D T Zava; A Wyler-von Ballmoos; A Goldhirsch; W Roos; A Takahashi; U Eppenberger; S Arrenbrecht; G Martz; G Losa; F Gomez; C Guelpa
Journal:  Eur J Cancer Clin Oncol       Date:  1982-08
View more
  4 in total

1.  Reverse transcription-polymerase chain reaction (RT-PCR) assays of estrogen and progesterone receptors in breast cancer.

Authors:  S Chevillard; A Müller; C Levalois; C Lainé-Bidron; P Vielh; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).

Authors:  Hratch Arbach; Viktor Viglasky; Florence Lefeu; Jean-Marc Guinebretière; Vanessa Ramirez; Nadège Bride; Nadia Boualaga; Thomas Bauchet; Jean-Philippe Peyrat; Marie-Christine Mathieu; Samia Mourah; Marie-Pierre Podgorniak; Jean-Marie Seignerin; Kenzo Takada; Irène Joab
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Prognostic and predictive value of low estrogen receptor expression in breast cancer.

Authors:  A Bouchard-Fortier; L Provencher; C Blanchette; C Diorio
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

4.  Prognostic factors in 1,038 women with metastatic breast cancer.

Authors:  R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey
Journal:  Ann Oncol       Date:  2008-07-17       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.